These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39120040)

  • 1. Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting.
    Kikuchi T; Tsukada N; Kunisada K; Matsumoto C; Nomura-Yogo M; Oda Y; Sato K; Takei T; Ogura M; Abe Y; Suzuki K; Hosoya O; Ishida T
    Hematol Oncol; 2024 Sep; 42(5):e3306. PubMed ID: 39120040
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
    Dima D; Mansour R; Davis JA; Minchak M; Goel U; Atallah R; Logan E; Tabak C; Rashid A; Ahmed N; Abdallah AO; Hashmi H
    Eur J Haematol; 2024 Jun; 112(6):975-983. PubMed ID: 38382632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
    Touzeau C; Perrot A; Hulin C; Manier S; Macro M; Chretien ML; Karlin L; Escoffre M; Jacquet C; Tiab M; Leleu X; Avet-Loiseau H; Jobert A; Planche L; Corre J; Moreau P
    Blood; 2024 May; 143(20):2029-2036. PubMed ID: 38394666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting.
    Kikuchi T; Tsukada N; Kunisada K; Matsumoto C; Nomura-Yogo M; Oda Y; Sato K; Takei T; Ogura M; Abe Y; Suzuki K; Hosoya O; Ishida T
    Ann Hematol; 2024 Sep; 103(9):3811-3813. PubMed ID: 38839622
    [No Abstract]   [Full Text] [Related]  

  • 6. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
    Quach H; Nooka A; Samoylova O; Venner CP; Kim K; Facon T; Spencer A; Usmani SZ; Grosicki S; Suzuki K; Delimpasi S; Weisel K; Obreja M; Zahlten-Kumeli A; Mateos MV
    Br J Haematol; 2021 Aug; 194(4):784-788. PubMed ID: 34046887
    [No Abstract]   [Full Text] [Related]  

  • 8. Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.
    Touzeau C; Antier C; Moreau P
    Future Oncol; 2021 Mar; 17(9):993-998. PubMed ID: 33289427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
    Højholt KL; Gregersen H; Szabo AG; Klausen TW; Levring MB; Preiss B; Helleberg C; Breinholt MF; Hermansen E; Rahbek Gjerdrum LM; Bønløkke ST; Nielsen K; Kjeldsen E; Iversen KF; Teodorescu EM; Kurt E; Strandholdt C; Andersen MK; Vangsted AJ
    Hematol Oncol; 2021 Oct; 39(4):521-528. PubMed ID: 34342035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
    Chen Y; Gopalakrishnan SK; Ooi M; Sultana R; Lim LH; Grigoropoulos N; Ong SY; Xu M; ; Chng WJ; Goh YT; Nagarajan C
    Blood Cancer J; 2021 Sep; 11(9):150. PubMed ID: 34480015
    [No Abstract]   [Full Text] [Related]  

  • 11. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
    Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
    Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
    Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
    Perrot A; Delimpasi S; Spanoudakis E; Frølund U; Belotti A; Oriol A; Moreau P; McFadden I; Xia Q; Arora M; Dimopoulos MA
    Leuk Lymphoma; 2024 Jun; 65(6):833-842. PubMed ID: 38497533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.
    Moreau P; Ghori R; Farooqui M; Marinello P; San Miguel J
    Br J Haematol; 2021 Jul; 194(1):e48-e51. PubMed ID: 34114211
    [No Abstract]   [Full Text] [Related]  

  • 16. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
    N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
    Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM; Chari A
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):701-710. PubMed ID: 34274290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.
    Elsada A; Adler AI
    Lancet Oncol; 2019 May; 20(5):619-620. PubMed ID: 30981602
    [No Abstract]   [Full Text] [Related]  

  • 19. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
    O'Donnell E; Mo C; Yee AJ; Nadeem O; Laubach J; Rosenblatt J; Munshi N; Midha S; Cirstea D; Chrysafi P; Horick N; Richardson PG; Raje N
    Lancet Haematol; 2024 Jun; 11(6):e415-e424. PubMed ID: 38677302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
    Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
    Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.